ClinicalTrials.gg
CompletedNCT05935033Updated Apr 4, 2025

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

A Phase 1 interventional study of Emraclidine in Hepatic Impairment, sponsored by AbbVie. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic impairment relative to matched participants with normal hepatic function.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. All Participants

    • Male and female participants, of ≥18.0 to 42.0 kilograms per meter square (kg/m\^2), inclusive, and a total body weight ≥50 kilograms (kg) (110 pounds [lbs]).
  2. Additional Inclusion Criteria for Participants With Normal Hepatic Function

    • Participants who are healthy, having no abnormalities. Have normal hepatic function.
    • (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and ≤ (ULN) and albumin ≥ lower limit of normal (LLN) and ≤ ULN. Participants with a history of Gilbert syndrome are eligible provided direct bilirubin fraction is \<20% of total bilirubin, and , and reticulocyte counts are all ≤ ULN.
  3. Additional Inclusion Criteria for Participants With Hepatic Impairment - Participants with stable hepatic impairment that meets the criteria for Class A, Class B, or Class C of the modified Classification. Stable hepatic disease defined as no clinically significant change in disease status in the last 28 days prior to the screening visit.

Key Exclusion Criteria:

  1. For All Participants

    • Any condition or surgery that could possibly affect drug absorption, including, but not limited to, bowel resections, bariatric weight loss surgery/procedures, gastrectomy, and cholecystectomy.
    • Receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination or booster within 7 days of planned dosing.
    • Have recently been diagnosed with symptomatic coronavirus disease 2019 (COVID-19) or test positive for SARS-CoV-2 within 15 days prior to signing the form (ICF).
    • Positive drug screen or a positive test for alcohol at Screening or Baseline (Check-in/Day -1) Visits.
    • Use of prohibited medications prior to randomization or likely to require prohibited concomitant therapy during the trial.
    • Current use of tobacco or nicotine-containing products (cigarettes, cigars, chewing tobacco, snuff, e-cigarettes, etc). Note: Light smokers (\<5 cigarettes/day or equivalent) are allowed provided they abstain from the use of tobacco- or nicotine-containing products for at least 2 hours prior to PK assessments.
    • Known allergy or to the medicinal product (IMP), closely related compounds, or any of their specified ingredients.
    • Has received IMP in a clinical trial of emraclidine within 12 months of signing the ICF.
    • Participants with a 12-lead demonstrating any of the following at the Screening Visit and at Check-in (Day -1):

      • corrected for heart rate using Fridericia's formula (QTcF) interval >470 milliseconds (ms)
      • QRS interval >120 ms (unless right bundle branch block)
      • PR interval >200 ms
      • Left ventricular hypertrophy (LVH) with ST depressions and/or T wave inversions in leads with relatively tall R waves (ie, LVH with associated ST-T wave abnormalities)
      • Type 2 second-degree or third-degree atrioventricular block
      • Heart rate \<45 beats per minute (bpm) or >100 bpm
      • Abnormal ECG changes (such as clinically significant ST depression or elevation or T wave inversion).
      • Abnormal heart rhythm (such as atrial fibrillation and atrial flutter)
    • Blood pressure measurements demonstrating any of the following at the Screening Visit and/or at Check-in (Day -1):

      • Supine systolic blood pressure ≥140 millimeters of mercury (mmHg) and/or diastolic blood pressure ≥90 mmHg
      • Standing systolic and/or diastolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg
      • Orthostatic hypotension, defined as a decrease of ≥20 mmHg in systolic blood pressure and/or ≥10 mmHg in diastolic blood pressure after at least 2 minutes of standing compared with the average of the resting supine blood pressure measurements.
  2. Additional Exclusion Criteria for Participants with Hepatic Impairment

    • Estimated (eGFR) \<60 mL/min/1.73m\^2 based on the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation at Screening or Check-in (Day -1) visits
    • Acute hepatitis
    • Grade ≥2 hepatic encephalopathy
    • Participants who have received an organ transplant or are currently waiting for an organ transplant and are listed on the national transplant list.
    • Primary biliary cholangitis or primary sclerosing cholangitis
    • ALT or AST >5 × ULN or alkaline phosphatase >2 × ULN. Participants with a history of Gilbert syndrome are eligible provided direct bilirubin fraction is \<20% of total bilirubin.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Severe Hepatic Impairment

    Participants will receive a single oral dose of 10 milligrams (mg) emraclidine.

    Drug: Emraclidine

  • Experimental
    Moderate Hepatic Impairment

    Participants will receive a single oral dose of 10 mg emraclidine.

    Drug: Emraclidine

  • Experimental
    Mild Hepatic Impairment

    Participants will receive a single oral dose of 10 mg emraclidine.

    Drug: Emraclidine

  • Experimental
    Normal Hepatic Function

    Participants will receive a single oral dose of 10 mg emraclidine.

    Drug: Emraclidine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 7

  2. Maximum Observed Unbound Plasma Concentration (Cmax,u) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 7

  3. Area Under the Plasma Concentration-time Curve from Time Zero to t (AUC0-t) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 7

  4. Area Under the Unbound Plasma Concentration-time Curve from Time Zero to t (AUC0-t,u) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 7

  5. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 7

  6. Area Under the Unbound Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf,u) of Emraclidine

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 7

Secondary outcomes

  1. Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Day 1 up to Follow-up (Day 15)

  2. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values

    Time frame: Days 1 to 7

  3. Number of Participants With Clinically Significant Changes in Vital Signs

    Time frame: Days 1 to 7

  4. Number of Participants With Clinically Significant Changes in Laboratory Assessments

    Time frame: Days 1 to 7

  5. Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results

    Time frame: Days 1 to 7

  6. Changes in Columbia Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

    Time frame: Days 1 to 7

07

Study locations

3 sites
  • Miami, Florida
    Miami, Florida 33136, United States
  • Orlando, Florida
    Orlando, Florida 32809, United States
  • San Antonio, Texas
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Feb 2025, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 7, 2023
StartActual
Jun 30, 2023
Primary completionActual
Feb 21, 2025
CompletionActual
Feb 21, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05935033
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 7, 2023
Start date
Jun 30, 2023
Primary completion
Feb 21, 2025
Completion
Feb 21, 2025
Last update
Apr 4, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion